

Accepted Manuscript

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer

Masaya Yotsukura, MD, Takashi Ohtsuka, MD, Kaoru Kaseda, MD, Ikuo Kamiyama, MD, Yuichiro Hayashi, MD, Hisao Asamura, MD

PII: S1556-0864(16)30461-0

DOI: [10.1016/j.jtho.2016.04.029](https://doi.org/10.1016/j.jtho.2016.04.029)

Reference: JTHO 200

To appear in: *Journal of Thoracic Oncology*

Received Date: 31 January 2016

Revised Date: 5 April 2016

Accepted Date: 28 April 2016

Please cite this article as: Yotsukura M, Ohtsuka T, Kaseda K, Kamiyama I, Hayashi Y, Asamura H, Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer, *Journal of Thoracic Oncology* (2016), doi: 10.1016/j.jtho.2016.04.029.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer

Running head: Inflammation-based prognostic score in operable NSCLC

Masaya Yotsukura, MD¹, Takashi Ohtsuka, MD¹, Kaoru Kaseda MD¹,
Ikuro Kamiyama MD¹, Yuichiro Hayashi, MD², Hisao Asamura, MD¹

¹ Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan

² Department of Pathology, Keio University Hospital, Tokyo, Japan

Keywords: lung cancer, inflammation, prognostic factor

Word count: 3249

Address correspondence to: Dr. Hisao Asamura

Division of Thoracic Surgery,

Keio University School of Medicine,

35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

E-mail: hasamura@keio.jp

Tel: +81 (0) 3 5363 3806

Fax: +81 (0) 3 5363 3499

Funding: This study was supported by unrestricted institutional funds from Eli Lilly Japan K.K., Pfizer Japan Inc., Shionogi & Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Taiho Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., and Covidien Japan Inc.

Conflict of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Download English Version:

<https://daneshyari.com/en/article/6192649>

Download Persian Version:

<https://daneshyari.com/article/6192649>

[Daneshyari.com](https://daneshyari.com)